Dual antiplatelet therapy is noninferior to alteplase for patients with minor nondisabling acute ischemic stroke – the ARAMIS trial
1. The ARAMIS trial revealed that the rate of favourable neurologic function at 90 days was 93.8% among patients assigned ...



![ABCD2 Score: Predicting Early Stroke Risk After Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg)




